Exact Sciences Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Exact Sciences Corp 公司

Exact Sciences Corporation 是一家全球先進的癌症診斷公司。該公司提供一系列用於早期癌症檢測和治療指導的產品。其產品和服務專注於篩查和精準腫瘤學測試。該公司的研發工作主要集中在三個主要領域：結直腸癌篩查、MCED 測試開發和 MRD 測試開發。該公司的產品和服務包括 Cologuard 測試、Oncotype DX 乳腺復發評分測試、Oncotype DX 乳腺 DCIS 評分測試、Oncotype DX 結腸復發評分測試和 OncoExTra 測試。該公司的旗艦篩查產品 Cologuard 測試是一種非侵入性、基於糞便的脫氧核糖核酸 (sDNA) 篩查測試，它利用多目標方法檢測與結直腸癌和癌前病變相關的 DNA 和血紅蛋白生物標誌物。Oncotype DX 乳腺復發評分測試檢查患者乳腺腫瘤組織中 21 個基因的活性。

公司簡介

公司代碼EXAS

公司名稱Exact Sciences Corp

上市日期Jan 30, 2001

成立日期1995

CEOMr. Kevin T. Conroy

員工數量6900

證券類型Ordinary Share

年結日Jan 30

公司地址5505 Endeavor Lane

城市MADISON

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編53719

電話16082845700

網址https://www.exactsciences.com/

公司代碼EXAS

上市日期Jan 30, 2001

成立日期1995

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.43M

+1.26%

Ms. Katherine S. (Kay) Zanotti

Independent Director

70.57K

+9.19%

Mr. Everett V. Cunningham

Executive Vice President

47.61K

-0.28%

Mr. Daniel J. (Dan) Levangie

Independent Director

28.91K

+25.85%

Ms. Shacey Petrovic

Independent Director

23.50K

+33.82%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.05K

+74.44%

Mr. Aaron Bloomer

Chief Financial Officer

13.62K

--

Ms. Kimberly J. (Kim) Popovits

Director

6.39K

--

Mr. James E. Doyle

Lead Independent Director

--

Ms. Kathleen Sebelius

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.43M

+1.26%

Ms. Katherine S. (Kay) Zanotti

Independent Director

70.57K

+9.19%

Mr. Everett V. Cunningham

Executive Vice President

47.61K

-0.28%

Mr. Daniel J. (Dan) Levangie

Independent Director

28.91K

+25.85%

Ms. Shacey Petrovic

Independent Director

23.50K

+33.82%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.05K

+74.44%

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Commercial

1.31B

47.44%

Medicare Parts B & C

964.10M

34.95%

Other

296.74M

10.76%

International

189.09M

6.85%

COVID 19 testing

0.00

0.00%

地區USD

名稱

營收

佔比

United States (Country)

2.57B

93.15%

Outside of united states

189.09M

6.85%

業務

地區

業務USD

名稱

營收

佔比

Commercial

1.31B

47.44%

Medicare Parts B & C

964.10M

34.95%

Other

296.74M

10.76%

International

189.09M

6.85%

COVID 19 testing

0.00

0.00%

股東統計

更新時間: 4月26日週六

持股股東

股東類型

持股股東

股東統計

佔比

Fidelity Management & Research Company LLC

10.15%

Capital World Investors

9.44%

The Vanguard Group, Inc.

9.12%

Wellington Management Company, LLP

6.49%

BlackRock Institutional Trust Company, N.A.

4.13%

Other

60.67%

持股股東

股東統計

佔比

Fidelity Management & Research Company LLC

10.15%

Capital World Investors

9.44%

The Vanguard Group, Inc.

9.12%

Wellington Management Company, LLP

6.49%

BlackRock Institutional Trust Company, N.A.

4.13%

Other

60.67%

股東類型

股東統計

佔比

Investment Advisor

51.55%

Investment Advisor/Hedge Fund

36.05%

Hedge Fund

6.23%

Research Firm

2.45%

Bank and Trust

1.53%

Pension Fund

1.22%

Individual Investor

1.08%

Sovereign Wealth Fund

0.50%

Private Equity

0.37%

機構持股

更新時間: 1月20日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

1377

200.62M

108.03%

+569.91K

2024Q4

1411

200.72M

108.09%

-225.66K

2024Q3

1375

190.82M

103.28%

-5.17M

2024Q2

1358

185.25M

100.40%

+6.59M

2024Q1

1347

168.41M

92.78%

-6.10M

2023Q4

1356

165.31M

91.41%

-11.01M

2023Q3

1337

167.70M

92.83%

-6.22M

2023Q2

1354

166.38M

92.24%

-10.65M

2023Q1

1343

167.01M

92.90%

-8.56M

2022Q4

1337

163.71M

92.15%

-9.28M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

18.85M

10.15%

-712.35K

-3.64%

Dec 31, 2024

Capital World Investors

17.54M

9.44%

+1.70M

+10.71%

Dec 31, 2024

The Vanguard Group, Inc.

16.95M

9.12%

-741.47K

-4.19%

Dec 31, 2024

Wellington Management Company, LLP

12.06M

6.49%

-2.27M

-15.86%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

7.66M

4.13%

+245.10K

+3.30%

Dec 31, 2024

State Street Global Advisors (US)

6.23M

3.36%

-447.40K

-6.70%

Dec 31, 2024

T. Rowe Price Associates, Inc.

5.62M

3.03%

+2.48M

+78.79%

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

4.27M

2.3%

+876.99K

+25.85%

Dec 31, 2024

William Blair Investment Management, LLC

3.44M

1.85%

-840.44K

-19.61%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.12M

1.68%

+16.83K

+0.54%

Dec 31, 2024

持股ETF

更新時間: 4月6日週日

機構名稱

佔比

First Trust Nasdaq Lux Digi Health Solutions ETF

2.94%

First Trust NYSE Arca Biotechnology Index Fund

2.61%

Invesco Biotechnology & Genome ETF

2.34%

SPDR S&P Biotech ETF

2.09%

Nuveen ESG Mid-Cap Growth ETF

1.77%

Franklin Genomic Advancements ETF

1.42%

iShares Health Innovation Active ETF

1.39%

Direxion Daily S&P Biotech Bull 3X Shares

1.33%

ROBO Global Healthcare Technology & Innovation ETF

1.28%

VanEck Biotech ETF

1.17%

First Trust Nasdaq Lux Digi Health Solutions ETF

佔比2.94%

First Trust NYSE Arca Biotechnology Index Fund

佔比2.61%

Invesco Biotechnology & Genome ETF

佔比2.34%

SPDR S&P Biotech ETF

佔比2.09%

Nuveen ESG Mid-Cap Growth ETF

佔比1.77%

Franklin Genomic Advancements ETF

佔比1.42%

iShares Health Innovation Active ETF

佔比1.39%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.33%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.28%

VanEck Biotech ETF

佔比1.17%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Exact Sciences Corp

45.925USD

Exact Sciences Corp

45.925

概覽

公司